advertisement

You are here: HomeTechnologyBharat Biotech's Covaxin recommended for phase 2/3 trials on 2-18 year-olds

Bharat Biotech's Covaxin recommended for phase 2/3 trials on 2-18 year-olds

Written by  Published in Technology Saturday, 23 September 2017 10:03
Rate this item
(0 votes)

Covaxin, indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), is being used in adults in India's ongoing Covid-19 vaccination drive.

Bharat Biotech's Covid-19 vaccine Covaxin was on Tuesday recommended by an expert panel for phase II/III clinical trial on those aged between two to 18 years, official sources said.

The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur.

The Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organization (CDSCO) on Tuesday deliberated upon Hyderabad-based Bharat Biotech's application seeking permission to conduct phase II/III clinical trials to evaluate the safety, reactogenicity and immunogenicity of Covaxin jabs in children aged 2 to 18 years. "After detailed deliberation, the committee recommended for conduct of proposed phase II/III clinical trial of whole virion inactivated coronavirus vaccine in the 2 to 18 years age group subject to the condition that the firm should submit the interim safety data of phase II clinical trial along with DSMB recommendations to the CDSCO before proceeding to phase III part of the study," a source said.

Earlier the proposal was deliberated in the SEC meeting dated February 24 and the firm was asked to submit a revised clinical trial protocol.

Covaxin, indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), is being used in adults in India's ongoing Covid-19 vaccination drive. Source : ht

 

Submit to DeliciousSubmit to DiggSubmit to FacebookSubmit to Google PlusSubmit to StumbleuponSubmit to TechnoratiSubmit to TwitterSubmit to LinkedIn
Read 365 times Last modified on Wednesday, 12 May 2021 07:00

Login to post comments

Contact Us


    • Address: 1/24, KMT Bhawan, 2nd Floor street no. 2, Lalita Park, Laxmi Nagar, Delhi 92
    • Mob: +91.9213493068, 9910636345
    • Email:  This email address is being protected from spambots. You need JavaScript enabled to view it.
    • Website: http://aihranews.org/

About Us

AIHRA is one of the renowned media group in print and web media. It has earned appreciation from various eminent media personalities and readers. ‘AIHRA’ is founded by Mr. M U Dua.